Multiple Myeloma
January 2019 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Multiple Myeloma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Multiple Myeloma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Multiple Myeloma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Multiple Myeloma every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Therapeutic antibodies for multiple myeloma.
Authors:Ishida T
Institution:Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Journal:Jpn J Clin Oncol. 2018 Nov 1;48(11):957-963. doi: 10.1093/jjco/hyy133.

2:Drug resistance in multiple myeloma.
Authors:Robak P, Drozdz I, Szemraj J, Robak T
Institution:Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland. address: robaktad@csk.umed.lodz.pl.
Journal:Cancer Treat Rev. 2018 Nov;70:199-208. doi: 10.1016/j.ctrv.2018.09.001. Epub 2018 Sep 4.

3:Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside.
Authors:Perrot A, Corre J, Avet-Loiseau H
Institution:From the Hematology Department, University Hospital, Nancy, France; Myeloma Genomics Laboratory, University Hospital, Toulouse, France; and Myeloma Genomics Laboratory, University Hospital, Toulouse, France.
Journal:Am Soc Clin Oncol Educ Book. 2018 May 23;(38):675-680. doi: 10.1200/EDBK_200879.

4:Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
Authors:Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, Evangelista A, Di Renzo N, Musto P, Marcatti M, Vallone R, Storti S, Bernardini A, Centurioni R, Aitini E, Palmas A, Annibali O, Angelucci E, Ferrando P, Baraldi A, Rocco S, Andriani A, Siniscalchi A, De Stefano V, Meneghini V, Palumbo A, Grammatico S, Boccadoro M, Larocca A
Institution:Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy. Electronic address: alessandra.larocca@unito.it.; Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy.; Divisione di Ematologia con Unita TMO, AO Cardarelli, Napoli, Italy.; Hematology and Stem Cell Transplant Unit, Regina Elena National Cancer Institute, Rome, Italy.; Section of Hematology with Transplantation, Department of Emergency and Organ Transplantation, University of Bari Medical School, Bari, Italy.
Journal:Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18.

5:The safety of bortezomib for the treatment of multiple myeloma.
Authors:Cengiz Seval G, Beksac M
Institution:a Ankara University Medical School, Department of Hematology , Cebeci Hospital , Ankara , Turkey. Ankara , Turkey.
Journal:Expert Opin Drug Saf. 2018 Sep;17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30.

6:Proteasome inhibitors for multiple myeloma.
Authors:Okazuka K, Ishida T
Institution:Department of Hematology, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan. Japan.
Journal:Jpn J Clin Oncol. 2018 Sep 1;48(9):785-793. doi: 10.1093/jjco/hyy108.

7:Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Authors:Zheng Y, Shen H, Xu L, Feng J, Tang H, Zhang N, Chen X, Gao G
Institution:Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Journal:J Immunol Res. 2018 Jun 27;2018:7646913. doi: 10.1155/2018/7646913. eCollection 2018.

8:Spinal metastases in multiple myeloma: A high-risk subgroup for ISS III patients.
Authors:Cossu G, Terrier LM, Benboubker L, Destrieux C, Velut S, Francois P, Zemmoura I, Amelot A
Institution:CHRU de Tours, Department of Neurosurgery, Tours, France; Lausanne University Hospital, Department of Neurosurgery, Switzerland. Francois-Rabelais de Tours, Inserm, Imagerie et cerveau, UMR U930, Tours, France. Francois-Rabelais de Tours, Inserm, Imagerie et cerveau, UMR U930, Tours, France. Francois-Rabelais de Tours, Inserm, Imagerie et cerveau, UMR U930, Tours, France. Francois-Rabelais de Tours, Inserm, Imagerie et cerveau, UMR U930, Tours, France. Pitie-Salpetriere, Department of Neurosurgery, Paris, France. Electronic address: aymmed@hotmail.fr.
Journal:Surg Oncol. 2018 Jun;27(2):321-326. doi: 10.1016/j.suronc.2018.05.005. Epub 2018 May 3.

9:Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Authors:Terpos E, Suzan F, Goldschmidt H
Institution:Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Electronic address: eterpos@med.uoa.gr. Center for Tumor Diseases (NCT), Heidelberg, Germany.
Journal:Crit Rev Oncol Hematol. 2018 Jun;126:19-23. doi: 10.1016/j.critrevonc.2018.03.021. Epub 2018 Mar 29.

10:How We Manage Patients with Plasmacytomas.
Authors:Fotiou D, Dimopoulos MA, Kastritis E
Institution:Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. ekastritis@gmail.com.
Journal:Curr Hematol Malig Rep. 2018 Jun;13(3):227-235. doi: 10.1007/s11899-018-0452-z.

11:Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Authors:Mushtaq A, Kapoor V, Latif A, Iftikhar A, Zahid U, McBride A, Abraham I, Riaz IB, Anwer F
Institution:Department of Medicine, Hematology and Oncology, University of Arizona, Tucson, AZ, United States. AZ, United States. AZ, United States. AZ, United States. AZ, United States; College of Public Health, University of Arizona, Tucson, AZ, United States. 85721, United States. United States. AZ, United States. Electronic address: anwerf@email.arizona.edu.
Journal:Crit Rev Oncol Hematol. 2018 May;125:1-11. doi: 10.1016/j.critrevonc.2018.02.008. Epub 2018 Mar 2.

12:Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?
Authors:Mian HS, Wildes TM
Institution:McMaster University, Hamilton, ON, Canada. St Louis, MO, 63110, USA. twildes@wustl.edu.
Journal:Drugs Aging. 2018 Apr;35(4):289-302. doi: 10.1007/s40266-018-0539-1.

13:Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Authors:Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B
Institution:Department of Pharmacy, Yangtze University Affiliated Hospital Jingzhou, Hangkong Street 8, Jingzhou, Hubei, 434000, China. mc1220@126.com. Jinlong Street 8, Jingzhou, Hubei, 434000, China. Street 8, Jingzhou, Hubei, 434000, China. Street 8, Jingzhou, Hubei, 434000, China. Street 8, Jingzhou, Hubei, 434000, China. Jingzhou, Hangkong Street 8, Jingzhou, Hubei, 434000, China.
Journal:Ann Hematol. 2018 Jun;97(6):925-944. doi: 10.1007/s00277-018-3284-y. Epub 2018 Mar 2.

14:Proteasome inhibitors for the treatment of multiple myeloma.
Authors:Scalzulli E, Grammatico S, Vozella F, Petrucci MT
Institution:a Hematology, Department of Cellular Biotechnologies and Hematology , "Sapienza" University , Rome , Italy. University , Rome , Italy. University , Rome , Italy. University , Rome , Italy.
Journal:Expert Opin Pharmacother. 2018 Mar;19(4):375-386. doi: 10.1080/14656566.2018.1441287. Epub 2018 Feb 26.

15:Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
Authors:McCullough KB, Hobbs MA, Abeykoon JP, Kapoor P
Institution:Department of Pharmacy Services, Mayo Clinic, Rochester, MN, USA. USA. USA. kapoor.prashant@mayo.edu.
Journal:Curr Hematol Malig Rep. 2018 Apr;13(2):114-124. doi: 10.1007/s11899-018-0443-0.

16:The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.
Authors:Cavo M, Terpos E, Bargay J, Einsele H, Cavet J, Greil R, de Wit E
Institution:a "Seragnoli" Institute of Hematology and Medical Oncology , Bologna University School of Medicine , Bologna , Italy. Athens School of Medicine , Athens , Greece. Spain. II , University Hospital Wurzburg , Wurzburg , Germany. Manchester , UK. and Molecular Cancer Research (LIMCR), Third Medical Department , Paracelsus Medical University, and Salzburg Cancer Research Institute , Salzburg , Austria.
Journal:Expert Rev Hematol. 2018 Mar;11(3):219-237. doi: 10.1080/17474086.2018.1437345. Epub 2018 Feb 16.

17:Immunopathogenesis and immunotherapy of multiple myeloma.
Authors:Tamura H
Institution:Department of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. tam@nms.ac.jp.
Journal:Int J Hematol. 2018 Mar;107(3):278-285. doi: 10.1007/s12185-018-2405-7. Epub 2018 Jan 24.

18:Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
Authors:Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA
Institution:Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. eterpos@med.uoa.gr.
Journal:Blood Cancer J. 2018 Jan 12;8(1):7. doi: 10.1038/s41408-017-0037-4.

19:The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
Authors:Comeau JM, Kelly K, Jean GW
Institution:University of Louisiana at Monroe, College of Pharmacy, Monroe, LA comeau@ulm.edu.
Journal:Am J Health Syst Pharm. 2018 Jan 15;75(2):55-66. doi: 10.2146/ajhp160554.

20:Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
Authors:Leleu X, Gay F, Flament A, Allcott K, Delforge M
Institution:Department of Haematology and CIC Inserm U1082, Hopital La Miletrie, Poitiers, France. xavier.leleu@chu-poitiers.fr. della Salute e della Scienza di Torino, Turin, Italy.
Journal:Ann Hematol. 2018 Mar;97(3):387-400. doi: 10.1007/s00277-017-3191-7. Epub 2017 Dec 27.

21:A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
Authors:Cook G, Zweegman S, Mateos MV, Suzan F, Moreau P
Institution:St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK. Electronic address: g.cook@leeds.ac.uk.
Journal:Crit Rev Oncol Hematol. 2018 Jan;121:74-89. doi: 10.1016/j.critrevonc.2017.11.016. Epub 2017 Dec 5.

22:Triplet vs. doublet drug regimens for managing multiple myeloma.
Authors:Offidani M, Corvatta L, Gentili S
Institution:a Clinica di Ematologia , Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona , Ancona , Italy. Italy. Italy.
Journal:Expert Opin Pharmacother. 2018 Feb;19(2):137-149. doi: 10.1080/14656566.2017.1418856. Epub 2017 Dec 21.

23:Upfront treatment of elderly myeloma patients: an overview and update.
Authors:Elsayed HG, Alabdulwahab AS
Institution:a Haematology Department , King Abdulla Medical City HC , Saudi Arabia. Cairo , Egypt.
Journal:Expert Rev Hematol. 2018 Feb;11(2):99-108. doi: 10.1080/17474086.2018.1419861. Epub 2018 Jan 10.

24:Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
Authors:Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC
Institution:Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong.
Journal:Leukemia. 2018 Feb;32(2):252-262. doi: 10.1038/leu.2017.329. Epub 2017 Nov 16.

25:Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Authors:Nijhof IS, van de Donk NWCJ, Zweegman S, Lokhorst HM
Institution:Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands. i.nijhof@vumc.nl.
Journal:Drugs. 2018 Jan;78(1):19-37. doi: 10.1007/s40265-017-0841-y.

26:Biology and treatment of myeloma related bone disease.
Authors:Terpos E, Christoulas D, Gavriatopoulou M
Institution:Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece. Electronic address: eterpos@med.uoa.gr.
Journal:Metabolism. 2018 Mar;80:80-90. doi: 10.1016/j.metabol.2017.11.012. Epub 2017 Nov 23.

27:A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
Authors:Offidani M, Corvatta L
Institution:Clinica di Ematologia Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Journal:Future Oncol. 2018 Feb;14(4):319-329. doi: 10.2217/fon-2017-0371. Epub 2017 Nov 1.

28:Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
Authors:Cole DC, Frishman WH
Journal:Cardiol Rev. 2018 May/Jun;26(3):122-129. doi: 10.1097/CRD.0000000000000183.

29:Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Authors:Yee AJ, Raje NS
Institution:Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. Boston, MA 02114, USA.
Journal:Future Oncol. 2018 Feb;14(3):195-203. doi: 10.2217/fon-2017-0403. Epub 2017 Oct 20.

30:Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.
Authors:Sahin U, Demirer T
Institution:Department of Hematology, Ankara University Medical School, Ankara, Turkey.
Journal:J Clin Apher. 2018 Jun;33(3):357-370. doi: 10.1002/jca.21591. Epub 2017 Oct 5.

31:Managing multiple myeloma in elderly patients.
Authors:Diamond E, Lahoud OB, Landau H
Institution:a Division of Hematologic Oncology, Department of Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
Journal:Leuk Lymphoma. 2018 Jun;59(6):1300-1311. doi: 10.1080/10428194.2017.1365859. Epub 2017 Aug 28.

For a FREE PREVIEW of the Medifocus Guidebook on Multiple Myeloma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Multiple Myeloma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Multiple Myeloma...
at a Special 20% Discount


Medifocus Guidebook on Multiple Myeloma

Updated: January 4, 2019
165 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Multiple Myeloma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MM73344042

Coupon Expires: March 23, 2019



What Our Customers Are Saying...

"The information in your MediFocus Guidebook on Multiple Myeloma was extremely useful. Thank you for providing this service."
K.J.
Milwaukee, Wisconsin


"I purchased the MediFocus Guidebook on Multiple Myeloma for my mother and it was a great help because it helped us to understand more about the disease, the causes, and the treatment options. Although there is no cure, it has helped us cope with the situation and helped us figure out how we can live with the disease."
J.M.
New York, New York


"My oncologist borrowed my copy of the MediFocus Guidebook on Multiple Myeloma and found it very useful in his work. He intends to contact your office."
D.S.
Miami Beach, Florida



  
Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2019 Medifocus, Inc. All rights reserved.